Drug intelligence / Profile preview

BI-765423

Development stage: Phase 2
Lead developer: Boehringer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BI-765423 is a first-in-class monoclonal antibody developed by Boehringer Ingelheim for the treatment of fibrotic diseases, with a primary focus on pulmonary fibrosis. It acts as an inhibitor of interleukin 11 (IL-11), a cytokine implicated in pro-fibrotic and pro-inflammatory processes. The drug is administered intravenously and is currently in Phase I clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. By targeting IL-11, BI-765423 aims to disrupt signaling pathways that contribute to tissue fibrosis[1][2][3][4].

Other names: anti-IL-11 antibodyanti-IL11 antibodyanti-IL 11 antibodyanti-interleukin-11 monoclonal antibodyanti-interleukin11 monoclonal antibodyanti-interleukin 11 monoclonal antibody

Targets

IL11 (Interleukin-11)

Beyond the preview

Go deeper on BI-765423.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI-765423.

Explore the full profile